Literature DB >> 12135541

The GABAergic system in schizophrenia.

Brian Paul Blum1, J John Mann.   

Abstract

A defect in neurotransmission involving gamma-amino butyric acid (GABA) in schizophrenia was first proposed in the early 1970s. Since that time, a considerable effort has been made to find such a defect in components of the GABAergic system. After a brief introduction focusing on historical perspectives, this paper reviews post-mortem and other biological studies examining the following components of the GABAergic system in schizophrenic subjects: the GABA biosynthetic enzyme, glutamate decarboxylase; free GABA; the GABA transporter; the GABAA, GABAB and benzodiazepine receptors; and the catabolic enzyme GABA transaminase. Additionally, post-mortem studies using morphology or calcium-binding protein to identify GABAergic neurons are also reviewed. Substantial evidence argues for a defect in the GABAergic system of the frontal cortex in schizophrenia which is limited to the parvalbumin-class of GABAergic interneurons.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12135541     DOI: 10.1017/S1461145702002894

Source DB:  PubMed          Journal:  Int J Neuropsychopharmacol        ISSN: 1461-1457            Impact factor:   5.176


  41 in total

1.  Loss of microRNAs in pyramidal neurons leads to specific changes in inhibitory synaptic transmission in the prefrontal cortex.

Authors:  Ruby Hsu; Claude M Schofield; Cassandra G Dela Cruz; Dorothy M Jones-Davis; Robert Blelloch; Erik M Ullian
Journal:  Mol Cell Neurosci       Date:  2012-06-20       Impact factor: 4.314

Review 2.  Glutamatergic postsynaptic density protein dysfunctions in synaptic plasticity and dendritic spines morphology: relevance to schizophrenia and other behavioral disorders pathophysiology, and implications for novel therapeutic approaches.

Authors:  Andrea de Bartolomeis; Gianmarco Latte; Carmine Tomasetti; Felice Iasevoli
Journal:  Mol Neurobiol       Date:  2013-09-03       Impact factor: 5.590

Review 3.  [Cortical excitability in schizophrenia. Studies using transcranial magnetic stimulation].

Authors:  T Wobrock; D Kadovic; P Falkai
Journal:  Nervenarzt       Date:  2007-07       Impact factor: 1.214

Review 4.  [Advances in neurobiological understanding of schizophrenia. Perspectives for new therapeutic concepts].

Authors:  P Falkai; W Maier
Journal:  Nervenarzt       Date:  2006-11       Impact factor: 1.214

Review 5.  The hemo-neural hypothesis: on the role of blood flow in information processing.

Authors:  Christopher I Moore; Rosa Cao
Journal:  J Neurophysiol       Date:  2007-10-03       Impact factor: 2.714

Review 6.  Multifunctional pharmacotherapy: what can we learn from study of selective serotonin reuptake inhibitor augmentation of antipsychotics in negative-symptom schizophrenia?

Authors:  Henry Silver; Yael Chertkow; Orly Weinreb; Lena Danovich; Moussa Youdim
Journal:  Neurotherapeutics       Date:  2009-01       Impact factor: 7.620

Review 7.  Antipsychotic drugs: comparison in animal models of efficacy, neurotransmitter regulation, and neuroprotection.

Authors:  Jeffrey A Lieberman; Frank P Bymaster; Herbert Y Meltzer; Ariel Y Deutch; Gary E Duncan; Christine E Marx; June R Aprille; Donard S Dwyer; Xin-Min Li; Sahebarao P Mahadik; Ronald S Duman; Joseph H Porter; Josephine S Modica-Napolitano; Samuel S Newton; John G Csernansky
Journal:  Pharmacol Rev       Date:  2008-09       Impact factor: 25.468

Review 8.  Searching human brain for mechanisms of psychiatric disorders. Implications for studies on schizophrenia.

Authors:  Sabina Berretta; Stephan Heckers; Francine M Benes
Journal:  Schizophr Res       Date:  2014-11-11       Impact factor: 4.939

9.  Elevated gamma-aminobutyric acid levels in chronic schizophrenia.

Authors:  Dost Ongür; Andrew P Prescot; Julie McCarthy; Bruce M Cohen; Perry F Renshaw
Journal:  Biol Psychiatry       Date:  2010-07-02       Impact factor: 13.382

10.  Common variants on Xq28 conferring risk of schizophrenia in Han Chinese.

Authors:  Emily H M Wong; Hon-Cheong So; Miaoxin Li; Quang Wang; Amy W Butler; Basil Paul; Hei-Man Wu; Tomy C K Hui; Siu-Chung Choi; Man-Ting So; Maria-Mercè Garcia-Barcelo; Grainne M McAlonan; Eric Y H Chen; Eric F C Cheung; Raymond C K Chan; Shaun M Purcell; Stacey S Cherny; Ronald R L Chen; Tao Li; Pak-Chung Sham
Journal:  Schizophr Bull       Date:  2013-09-16       Impact factor: 9.306

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.